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Abstract
Huntington’s disease (HD) is a progressive neurological disorder for which there are no disease-modifying treatments.
Transcriptional dysregulation is a major molecular feature of HD, which significantly contributes to disease progression.
Therefore, the development of histone deacetylase (HDAC) inhibitors as therapeutics for HD has been energetically pursued.
Suberoylanilide hydroxamic acid (SAHA) – a class I HDAC as well an HDAC6 inhibitor, improved motor impairment in the R6/
2 mouse model of HD. Recently it has been found that SAHA can also promote the degradation of HDAC4 and possibly
other class IIa HDACs at the protein level in various cancer cell lines. To elucidate whether SAHA is a potent modifier of
HDAC protein levels in vivo, we performed two independent mouse trials. Both WT and R6/2 mice were chronically treated
with SAHA and vehicle. We found that prolonged SAHA treatment causes the degradation of HDAC4 in cortex and brain
stem, but not hippocampus, without affecting its transcript levels in vivo. Similarly, SAHA also decreased HDAC2 levels
without modifying the expression of its mRNA. Consistent with our previous data, SAHA treatment diminishes Hdac7
transcript levels in both wild type and R6/2 brains and unexpectedly was found to decrease Hdac11 in R6/2 but not wild
type. We investigated the effects of SAHA administration on well-characterised molecular readouts of disease progression.
We found that SAHA reduces SDS-insoluble aggregate load in the cortex and brain stem but not in the hippocampus of the
R6/2 brains, and that this was accompanied by restoration of Bdnf cortical transcript levels.
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Introduction
Huntington’s disease (HD) is a progressive neurological disorder
for which there is no effective disease-modifying treatment [1,2].
The disease is caused by the expansion of a CAG repeat to more
than 35 CAGs within exon 1 of the HTT gene. This leads to a
wide-range of characteristic symptoms including personality
changes, motor impairment and weight loss, which progress over
the course of 15–20 years to death [3]. At the molecular level,
mutant huntingtin has a strong propensity to self-aggregate and
form a wide-range of oligomeric species as well as insoluble
aggregates [4,5,6,7] that lead to an imbalance in cellular
homeostasis [8]. As a consequence, one of the major molecular
features of HD is transcriptional dysregulation, which significantly
contributes to disease progression [9,10,11].
Globally, transcription is regulated at the level of chromatin by
a variety of epigenetic marks. This includes the covalent
modification of conserved lysine residues within histone proteins
and is orchestrated by histone acetylases (HATs) and histone
deacetylases (HDACs). Mammalian HDACs are a family of 18
molecules divided into four groups based on structural and
functional similarities: class I (HDACs: 1, 2, 3, 8), class IIa
(HDACs: 4, 5, 7, 9), class IIb (HDACs: 6, 10), class III (sirtuins 1–
7) and HDAC11 as the sole member of class IV [12]. In HD, it has
been proposed that an imbalance in histone acetylation is caused
by the inactivation of HATs [13,14,15]. Hence, abnormal histone
acetylation and chromatin remodelling might be a key process
leading to transcriptional dysregulation [16]. Therefore, much
effort has been directed towards developing HDAC inhibitors as
an HD therapeutic [17] and initial genetic studies performed in
flies and worms have confirmed that these may have a significant
potential [14,18,19].
Preclinical evaluation of the HDAC inhibitor suberoylanilide
hydroxamic acid (SAHA) demonstrated a dramatic improvement
of the motor impairment in the R6/2 mouse model of HD [20].
Initially, SAHA was shown to inhibit members of class I and class
II HDACs at nanomolar concentrations [21], but is predomi-
nantly an inhibitor of class I HDACs as well as the class IIb
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have been used to demonstrate that SAHA can bind to both class I
and IIa HDACs [24,25]. Furthermore, it has been shown that in
cancer cell lines, SAHA can lead to the degradation of class IIa
HDACs 4 and 5 via RANBP2 mediated proteasome degradation
in vitro [26]. We are currently exploring the potential mechanisms
by which SAHA might act to improve HD-related symptoms in a
mouse model of HD. In this study we have investigated whether
the chronic treatments of SAHA might result in the degradation of
class IIa HDACs in vivo.
Results
In order to determine whether SAHA results in a reduction of
class IIa HDACs at the protein level in vivo, WT and R6/2 mice
were administered vehicle or SAHA in the drinking water
(0.67 mg/ml) from five to nine weeks of age as previously
described [20]. HDAC4 protein levels were measured in three
different brain regions: cortex, hippocampus and brain stem
(Fig. 1) by SDS-PAGE and immunoblotting with an N-terminal
anti-HDAC4 antibody (Sigma) as well as with an HDAC4
antibody that had been raised against a peptide adjacent to the
deacetylase domain (Santa Cruz). We observed a significant
reduction in HDAC4 in the cortex and brain stem but not in the
hippocampus of both WT (Fig. 1A) and R6/2 (Fig. 1B) mice
treated with SAHA as compared to vehicle.
We have previously shown, that exposure to SAHA does not
modulate the formation of huntingtin aggregates in organotypic
hippocampal slice cultures prepared from R6/2 neonates [20]. At
that time, we did not have the means to quantitatively determine
the level of SDS-insoluble aggregates in brain tissue. However,
since then, we have developed the seprion-ligand ELISA, a highly
quantitative method with good statistical power that can be used
to measure changes in aggregate load that occur in vivo in
response to pharmacological or genetic manipulations [7].
Therefore we employed this assay to determine whether SAHA
can modulate huntingtin aggregatation in vivo. We found that
chronic treatment of R6/2 mice with SAHA significantly reduced
aggregation in the cortex and brain stem but not in the
hippocampus (Fig. 1C).
To confirm our results and extend our molecular analyses we
performed a second trial that replicated the original dosing
regimen. As found in the first trial, SAHA administration
decreased HDAC4 protein levels in the cortex and brain stem
but not in the hippocampus of both WT (Fig. 2A) and R6/2
(Fig. 2B) mice. We were intrigued to determine whether SAHA
targets HDAC4 at the protein level or whether it modulates the
Hdac4 transcript. Due to the limited amount of hippocampal
tissues, HDAC4 transcript levels were only assessed in the cortex
and brain stem. Quantitative RT-PCR (qPCR) showed that there
was no difference in Hdac4 mRNA levels between vehicle treated
WT and R6/2 mice and that SAHA did not affect Hdac4 mRNA
levels in either WT or R6/2 mice (Fig. 2C). The seprion-ligand
ELISA confirmed that there was a significant reduction in SDS
insoluble aggregate load in the brain stem of R6/2 treated mice at
9 weeks of age and a trend toward reduction in the cortex (Fig. 3A).
Again, no change in aggregate load was found in the hippocampus
(Fig. 3A). To ensure that the decrease in aggregate load had not
occurred as a consequence of a reduction in the expression of the
R6/2 mutant exon 1 huntingtin transgene (mt-exon 1), we
performed qPCR and found that the level of the R6/2 trangene
was not altered upon SAHA administration (Fig. 3B).
It is well established that brain derived neurotophic factor
(BDNF) plays a crucial role in HD pathogenesis [27], that Bdnf
transcript levels diminish during desease progression in the R6/2
mouse model [28] and that over-expession of BDNF ameliorates
HD-related phenotypes in mice [29]. Therefore we were interested
in determining whether SAHA might modulate Bdnf transcript
levels. We used a qPCR assay designed to detect the levels of the
BDNF protein coding region. As predicted, Bdnf transcript levels
were reduced in the R6/2 vehicle treated group as compared to
WT, and we found that its levels were partially restored upon
SAHA treatment (Fig. 3C). Interestingly, SAHA did not affect Bdnf
mRNA levels in WT mice as compared to those treated with
vehicle.
Next, we investigated whether chronic SAHA treatment can
affect the protein levels of other HDACs, especially the members
of the class IIa group. First, we screened a number of
commercially available antibodies raised against HDAC enzymes
and found that only antibodies for HDACs: 1, 2 and 3 (class I) and
HDACs: 5, 7 and 9 (class IIa) were suitable for immunodetection
in mouse tissues. We found that SAHA had no effect on the
protein levels of HDACs: 1, 3, 5, 7 and 9 in the cortex (Fig. 4A),
brain stem (data not shown) or hippocampus (data not shown) of
WT and R6/2 mice in comparison to their vehicle groups.
Suprisingly, we found that like HDAC4, SAHA decreased
HDAC2 protein levels in cortex (Fig. 4A) and brain stem
(Fig. 4B) but not hippocampus of the WT and R6/2 mice (data
not shown). To investigate the overall relationship between HDAC
mRNA and protein levels, we profiled the transcript levels of all 10
remaining HDACs by qPCR in the cortex and brain stem. As had
been found previously [30,31], SAHA significantly decreases
Hdac7 transcript levels in both brain regions (Fig. 5A, 5B).
However, the attenuation of Hdac7 mRNA levels was more
pronounced in the brain stem for both WT and R6/2 mice than in
the cortex (Fig. 5), likely due to the heterogeneity of cortical tissues.
In addition, we discovered that Hdac11 mRNA levels are
decreased upon SAHA treatment in the cortex and brain stem
of R6/2 mice but not WT mice (Fig. 5). In conclusion, SAHA
treatment resulted in a reduction in HDAC2 and HDAC4 at the
protein but not RNA level in some brain regions and that Hdac7
and Hdac11 were modulated at the RNA level.
Discussion
Suberoylanilide hydroxamic acid, known as SAHA or Vorino-
stat, was the first HDAC inhibitor to be approved for advanced
cutaneus T-cell lymphoma cancer therapy [32]. In addition, we
have shown SAHA to be a potent modulator of HD-related
phenotypes in the R6/2 mouse [20]. SAHA is predominantly an
Figure 1. Chronic administration of SAHA decreases HDAC4 levels and reduces aggregate load – 1
st trial. HDAC4 protein levels are
reduced in the cortex and brain stem, but not in the hippocampus of WT and R6/2 mice treated with SAHA. Representative western immunoblots of
20 mg of cortical, brain stem and hippocampal homogenates from 9-week-old WT (A) and R6/2 (B) mice treated with SAHA or vehicle, immunoprobed
with the Sigma (Fig. 1A, 1B - brain stem) or the Santa Cruz (Fig. 1A, 1B – cortex and hippocampus) anti-HDAC4 antibodies are shown. HDAC4 protein
levels were normalized to alpha-tubulin and quantified using densitometry. Representative graphs illustrate relative HDAC4 protein levels as a
percentage of the respective vehicle group. Error bars represent S.E.M. (n=4). The seprion-ligand ELISA was used to quantify aggregate loads, which
were significantly reduced in the cortex and brain stem but not in the hippocampus of the R6/2 SAHA treated mice (C). Error bars are S.E.M. (WT
vehicle: n=6; WT SAHA: n=6; R6/2 vehicle: n=6; R6/2 SAHA n=5).
doi:10.1371/journal.pone.0027746.g001
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IIa HDACs [24,25] and has been shown to degrade class IIa
HDACs at the protein level in vitro [26]. Thus, in this study we
asked whether chronic treatment of SAHA might result in the
degradation of class IIa HDACs in both wild type and R6/2 mice
in vivo.
We had previously found that SAHA could be solubilised by
complexing it with hydroxypropyl-b-cyclodextrins [20], a process
that required boiling the reagents, and could conceivably affect its
stability. Therefore, we assessed the stability and purity of SAHA
in this formulation when incubated at room temperature for a
period of up to seven days. We were reassured to find that the
concentration of SAHA did not change during this period and that
its purity remained at .99% (Fig. S1A). Similarly, the brain
pharmacokinetic profile of SAHA has not previously been
published. As expected we found that SAHA was brain penetrant,
but was cleared rapidly from both plasma and brain and that the
brain:plasma ratio was ,0.12 at most time points (Fig. S1B).
SAHA was administered to wild type and R6/2 mice at a
concentration of 0.67 mg/ml in drinking water over a period of 4
weeks. We performed western blotting on lysates from the cortex,
brain stem and hippocampus to determine the levels of the class I
enzymes: HDACs 1–3 and all of the class IIa HDACs. We found
that HDAC2 and HDAC4 levels decreased upon SAHA treatment
to approximately 30% in the cortex and brain stem but not in the
hippocampus of both WT and R6/2 mice. This discrepancy
between brain regions might be explained by brain-region
dependent exposure to SAHA, or at least in the case of HDAC4,
due to its high hippocampal expression level [33]. Alternatively, as
HDAC inhibitors have been shown to display different properties
in various cell lines [34], the discrepancy could be due to variation
in the cell-type composition of the brain regions. We did not detect
changes in the protein level of the other class I (HDAC1 and 3) or
class IIa (HDACs 5, 7 and 9) enzymes and were not able to assess
protein levels of HDACs 6, 8, 10 and 11 due to the lack of
available antibodies. To investigate whether the changes in
HDAC2 and HDAC4 levels were a consequence of decreased
gene expression, we prepared a set of qPCR assays to measure the
transcript levels of all Hdacs. We found that the mRNA levels of
Hdac2 and Hdac4 remained unchanged in SAHA treated tissues.
Therefore, we might speculate that the mechanism through which
SAHA leads to a reduction in HDAC4 is through RANBP2-
mediated proteasome degradation as determined for cancer cell
lines [26]. As previously described, we found that SAHA reduces
Hdac7 transcript levels [30,31], although we have previously shown
that the genetic reduction of Hdac7 does not alleviate HD-
phenotypes in the R6/2 mouse [31]. In addition, Hdac11 mRNA
levels were decreased in R6/2 but not in wild type cortex and
brain stem upon SAHA treatment. Unfortunately, because of the
lack of an HDAC11 antibody, we were unable to determine if this
translated to the protein level. Interestingly, HDAC11 has been
identified as a molecular target that controls immune activation
versus immune tolerance through Interleukin 10 [35], an
inhibitory cytokine that is up-regulated in HD post mortem brains
[36].
We have recently developed the seprion-ligand ELISA to
quantify the aggregate load in tissues samples from mouse models
of HD [7]. This assay has good statistical power to detect small
changes in aggregation that occur due to therapeutic interventions
administered to R6/2 mice from five to nine weeks of age [37].
Therefore, we measured the aggregate load in the cortex, brain
stem and hippocampus of R6/2 mice that had been treated with
SAHA over this four week period. We found that there was a
statistically significant reduction in aggregation in the cortex and
brain stem, but not in the hippocampus, which correlates with the
reduction in HDAC2 and HDAC4 levels. The hippocampal data
are consistent with our previous finding that SAHA treatment did
not inhibit polyQ aggregation in hippocampal slice cultures from
R6/2 mice [20]. We also found that there was a partial restoration
in the expression level of the Bdnf protein coding exon. Our in vivo
finding, that SAHA increases expression of Bdnf, correlates with
previous in vitro study in the neuron-glia cultures, indicating that
HDAC inhibitors up-regulate Bdnf expression [38]. Moreover, we
confirmed that the improvement in these molecular phenotypes
had not arisen through a decrease in the expression of the R6/2
transgene.
HDAC inhibitors have been shown to consistently improve the
phenotypes of HD mouse models [20,39,40] and are being
developed as HD therapeutics. Our demonstration that the
administration of SAHA to wild type and R6/2 mice decreases
the levels of HDAC2 and HDAC4 at the protein and not RNA
levels extends previous observations in cancer cell lines to the in
vivo situation. In addition, a recent study has demonstrated that
trichostatin A (TSA) and sodium butyrate also result in a reduction
in HDAC4 when administered to embryoid bodies [41].
Consistent with the work described by Scognamiglio [26] they
also show that this occurs through a proteasome-dependent
mechanism [41] and arises as a general consequence of HDAC
inhibitor action. Therefore, the beneficial effects of HDAC
inhibitors in the context of HD might be more complex than
previously anticipated and encompass decreased class I deacety-
lase activity, increased degradation of HDAC2 and/or HDAC4
and a reduction in the transcription of Hdac11.
Materials and Methods
Ethics statement
All experimental procedures performed on mice were approved
by the King’s College London Ethical Review Process Committee
and carried out under the UK Home Office License 70/6545.
SAHA formulation, purity and stability
For chronic administration via drinking water, SAHA was
complexed at a 1:5 molar ratio with hydroxypropyl-b-cyclodextrin
97% (Acros Organics, Cat. No.: 297561000, Lot no. A0272247) in
deionised, filtered, irradiated water. SAHA was prepared at a
concentration of 0.67 mg/ml in 5M hydroxypropyl-b-cyclodextrin
and solubilisation was achieved by boiling for two minutes
followed by cooling slowly to room temperature for approximately
2 hours. LC-MS/MS analysis was employed to ensure the purity
Figure 2. Chronic administration of SAHA decreases HDAC4 protein but not mRNA levels – 2
nd trial. HDAC4 protein levels are reduced
in the cortex and brain stem, but not in the hippocampus of WT and R6/2 mice treated with SAHA. Representative western immunoblots of 20 mgo f
cortical, brain stem and hippocampal homogenates from 9-week-old WT (A) and R6/2 (B) mice treated with SAHA or vehicle, immunoprobed with the
Santa Cruz anti-HDAC4 antibody are shown. HDAC4 protein levels were normalized to alpha-tubulin and quantified using densitometry.
Representative graphs illustrate relative HDAC4 protein levels as a percentage of the respective vehicle group. Error bars represent S.E.M. (n=4). C.
Hdac4 transcript levels were unaffected in the cortex and brain stem of the WT and R6/2 SAHA treated mice. Hdac4 mRNA expression levels are
shown as a relative expression ratio to the geometric mean of three housekeeping genes in the cortex and brain stem of 9-week-old WT vehicle (red
bars), WT SAHA (blue bars), R6/2 vehicle (yellow bars) and R6/2 SAHA (green bars) mice. Error bars are S.E.M (n=6). NS=not specific.
doi:10.1371/journal.pone.0027746.g002
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[1.75 mg/1.75 ml] solution of solid SAHA [C14H20N2O3;
MW 264.33] was prepared in 80/20 v/v acetonitrile/DMSO
for LC-MS purity analysis after diluting with 100 ml of DMSO.
LC-MS full scan [150–850 m/z] analysis was performed using
electrospray atmospheric pressure ionization source in positive ion
mode (ESI+) with HP Agilent 1100 binary pump coupled to
Waters ZQ single quadrupole mass spectrometer, Waters 2996
PDA and Waters 2420 ELS detectors. Analysis was performed on
a Waters Atlantis dC18 column 2.1 mm6100 mm, 3 mm using a
generic gradient with injection volume of 3 ml and flow rate of
0.6 ml/min with a total run time of 7 minutes. The mobile phase
(solvent A) comprised of water +0.1% formic acid and (solvent B)
acetonitrile +0.1% formic acid.
The UV purity of SAHA prepared from solid was .99%.
SAHA was formulated at 0.67 mg/ml as above and stored at RT.
Aliquots were removed on the day of formulation and after 2, 4
and 7 days and snap frozen. The concentration of SAHA
remained unchanged over the seven day period and the UV
purity remained .99% on day seven (Fig. S1A).
Pharmacokinetic study
WT and R6/2 female mice were subcutaneously injected with a
single dose of 200 mg/kg SAHA formulated with hydroxylpropyl-
b-cyclodextrin as stated above and tissues were harvested at 0.25,
0.5, 1, 2, 4, 8, 16 and 24 hours post dosing. Mice were deeply
anesthetised with Euthatal and blood was collected by cardiac
puncture into K2EDTA collection tubes (Greiner Bio-One).
Samples were centrifuged at 96006g for 10 min, the supernatant
was collected and frozen in liquid nitrogen. Brain tissues were
immediately frozen in liquid nitrogen.
The concentrations of SAHA in the mouse plasma and brain
were determined using an LC-MS/MS assay developed at
BioFocus. The lower limit of quantification (LLOQ) was 19 nM
for plasma and 3.8 nM for brain. Calibration standards for
plasma (5.00–10000 ng eq./ml) and brain (1.00–10000 ng eq./g)
were prepared by adding SAHA to control mouse plasma and
brain samples respectively. Diclofenac was used as an internal
standard in the LC-MS/MS assay, except for plasma, where a
difference in the internal standard response was seen between the
study and calibration samples. Therefore, the plasma data were
generated without normalizing the analytic response for internal
standard response. Calibration standards were prepared in
duplicate for each concentration and at a minimum, 75% of all
the calibration standards and at least one calibration standard per
concentration met the accuracy and precision criteria of 630%.
There was no bias in the accuracy or precision of the calibration
standards. The coefficient of variation (CV%) of the internal
standard signal/area response for the entire run was within the
criteria of 630%, and there was no bias or trend in the internal
standard signal/area response. Figure S1B shows the SAHA
concentrations measured in the plasma and brain tissues at
different time points.
Mouse maintenance and breeding
Hemizygous R6/2 mice were bred by backcrossing R6/2 males
to (CBA x C57BL/6) F1 females (B6CBAF1/OlaHsd, Harlan
Olac, Bicester, UK). All animals had unlimited access to water and
breeding chow (Special Diet Services, Witham, UK), and housing
conditions and environmental enrichment were as previously
described [42]. Mice were subject to a 12-h light/dark cycle. All
experimental procedures were performed according to Home
Office regulations.
Genotyping and CAG repeat sizing
Genomic DNA was isolated from an ear-punch. R6/2 mice
were genotyped by PCR as previously described and the CAG
repeat was measured by sequencing with an ABI3730 automated
sequencer as previously described [7].
Figure 3. Chronic administration of SAHA reduces aggregate
load and rescues Bdnf transcript levels without affecting mt-
Exon 1 transcript levels – 2
nd trial. The seprion-ligand ELISA was
used to quantify aggregate loads, which were found to be reduced in
the brain stem and cortex but not in the hippocampus of the R6/2
SAHA treated mice (A). Error bars are S.E.M. (n=6). Mt-Exon 1 transcript
levels in the cortex and brain stem of R6/2 vehicle and SAHA treated
mice were unchanged (B). Representative graphs show the crossing
threshold (Ct) of the mt-Exon 1 transcript levels for R6/2 vehicle and
SAHA treated mice. cDNA from vehicle and SAHA treated WT mice
served as a negative control (data not shown). Error bars are S.E.M
(n=6). Bdnf transcript levels were partially rescued in the cortex of
SAHA treated R6/2 mice but were unchanged in SAHA treated WT mice
(C). Bdnf mRNA expression levels were assessed by qPCR and presented
as a relative expression ratio to the geometric mean of three
housekeeping genes in the cortex of 9-week-old WT vehicle (red bars),
WT SAHA (blue bars), R6/2 vehicle (yellow bars) and R6/2 SAHA (green
bars) mice. Error bars are S.E.M (n=6). * p,0.05, ** p,0.01, ***
p,0.001.
doi:10.1371/journal.pone.0027746.g003
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In the case of both trials, female WT and R6/2 mice were
randomized from litters born over a period of 1 day. The number
of animals per treatment group and CAG repeat size are
summarised in Table S1. Mice were weaned into their treatment
groups at four weeks of age. Both trials were initiated at 5 weeks of
age and SAHA (0.67 mg/ml) or vehicle was administrated in
drinking water for 4 consecutive weeks (bottles with SAHA or
vehicle were changed on the weekly basis). Trials were terminated
at 9 weeks of age and all tissues were dissected, snap frozen in
liquid nitrogen and stored at 280uC until further analysis.
RNA extraction and Taqman real-time PCR expression
analysis
Total RNA from cortex and brain stem was extracted with the
mini-RNA kit according to manufacturer instructions (Qiagen).
The reverse transcription reaction (RT) was performed using
MMLV superscript reverse transcriptase (Invitrogen) and random
hexamers (Operon) as described elsewhere [28]. The final RT
reaction was diluted 10-fold in nuclease free water (Sigma) for
further Taqman-qPCR reactions. All Taqman-qPCR reactions
were performed as described previously [28], using the Chromo4
Real-Time PCR Detector (BioRad). Estimation of mRNA copy
number was determined in triplicate for each RNA sample by
comparison to the geometric mean of three endogenous
housekeeping genes (Primer Design) as described [28]. Primer
and probe sequences for HDACs 1–11 are presented in Table S2
and were purchased from Operon. Primer and probe sequences
for Bdnf and mt-exon 1 HTT were described previously [28].
Protein extraction from snap frozen tissues for
Immunoblotting and ELISA
Cortical, hippocampal and brain stem tissues were stored at
280uC. All protein lysates from tissues examined in this study
were prepared as 2.5% lysates (w/v) by homogenizing tissue with
ceramic beads (MP Biomedicals, lysing matrix D) in RIPA buffer
(1% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 1 mM b-mercaptoethanol, 100 mM
PMSF, 1 mM DTT) supplemented with protease inhibitor
cocktail (Roche). Homogenization was achieved by 2 runs for
Figure 4. SAHA treatment decreases HDAC2 protein levels but does not affect the protein levels of other class I and IIa HDACs – 2
nd
trial. HDAC2 protein levels are reduced in the cortex (A) and brain stem (B) but not in the hippocampus (data not shown) of WT and R6/2 SAHA as
compared to vehicle treated mice. Representative western immunoblots of 20 mg of cortical and brain stem homogenates from 9-week-old WT and
R6/2 SAHA and vehicle treated mice are shown. HDAC1, HDAC3, HDAC5, HDAC7 and HDAC9 protein levels do not change upon SAHA treatment of
WT or R6/2 mice in the cortex (A) nor in the brain stem or hippocampus (data not shown). In all cases, HDAC protein levels were quantified using
densitometry and normalized to alpha-tubulin. Error bars represent S.E.M. (n=4).
doi:10.1371/journal.pone.0027746.g004
Figure 5. Of the 11 HDACs, SAHA specifically down-regulates Hdac7 and Hdac11 at the mRNA in WT and R6/2 mice – 2
nd trial. Hdac7
and Hdac11 transcript levels were reduced in the cortex (A) and brain stem (B) of R6/2 mice treated with SAHA. Hdac expression levels are shown as
relative expression ratios to the geometric mean of three housekeeping genes in 9 week-old mouse WT vehicle (red bars), WT SAHA (blue bars), R6/2
vehicle (yellow bars) and R6/2 SAHA (green bars) mice. Error bars are S.E.M (n=6). * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0027746.g005
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MP Biomedicals). In between these cycles, the samples were
placed on ice for 5 minutes. Next, samples were snap frozen on
dry ice and thawed. At this stage, samples were used for the
seprion-ligand ELISA to capture huntingtin aggregates. For
immunoblotting, samples were sonicated with a Vibracell
sonicator (Sonics & Material Incorporated) at 40 Hz, with 10
pulses (1 second each), and placed on a spinning wheel at 4uC for
15 min. Purification was achieved by spinning the samples at
16,2006g for 15 min at 4uC. Protein concentration was measured
using the Pierce BCA assay kit (Thermo Scientific).
Antibodies and western blotting
20 mg protein lysate was fractionated on a 10% SDS-PAGE gel
and transferred to a Protran nitrocellulose membrane (Whatman)
by submerged transfer apparatus (Bio-Rad) in transfer buffer
(25 mM Tris-HCl, 192 mM glycine, 20%, v/v, methanol). 150 ug
protein lysates was used for HDAC7 detection. Membranes were
blocked for at least 30 minutes at room temperature in 0.1% PBS-
Tween20 (PBST) containing 5% non-fat dried milk. Next,
membranes were incubated with primary antibodies in 0.1%
PBST containing 1% non-fat dried milk with gentle agitation over
night at 4uC. The following primary antibodies were used:
HDAC1 (1:1000) from Sigma (H3284), HDAC2 (1:1000) from
Sigma (H3159), HDAC3 (1:1000) from Millipore (clone Y415),
HDAC4 (1:1000) from Santa Cruz (SC11418), HDAC4 (1:500)
Sigma (H9536), HDAC5 (1:1000) from Abcam (ab1439), HDAC7
(1:250) as described [31], HDAC9 (1:1000) from Biovision (3609-
100). a-tubulin (1:40,000) from Sigma was used as a loading
control. For chemiluminescent detection, blots were washed three
times in 0.1% PBST, then probed with HRP-linked secondary
antibodies (HRP conjugated anti-rabbit (1:20,000, Perbio) or anti-
mouse (1:5000, Daco) in 0.1% PBST for 1 hour at RT followed by
washing in 0.1% PBST. To detect signal by chemiluminescense,
the GE Healthcare Enhanced detection kit and Amersham
Hyperfilms (both from GE Healthcare) were used according to
the manufacturer’s instructions. The signals were quantified using
a GS-800 calibrated densitometer (Bio-Rad).
Seprion ligand ELISA
Aggregates were captured in seprion-ligand coated plates
(Microsens) and detected with the S830 sheep polyclonal antibody
as described [7].
Statistical analysis
All data were analysed with Microsoft Office Excel and
Student’s t-test (two tailed).
Supporting Information
Figure S1 Pharmacokinetic study and SAHA stability.
SAHA shows long-term stability when complexed with hydro-
xypropyl-b-cyclodextrin in water (A). The pharmacokinetic study
revealed SAHA to be a brain penetrant compound with fast
clearance characteristics (B).
(TIF)
Table S1 Number of animals per treatment group and
CAG repeat size.
(DOC)
Table S2 Primers and probes sequence for Hdacs 1–11.
(DOC)
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